Share

Biogen's Alzheimer's drug trial ripe for downside: Analyst

Brian Skorney, analyst at Baird, downgraded Biogen. Skorney joins CNBC's "Power Lunch" team to discuss his call.
04:04
Mon, Dec 2 20192:56 PM EST